Dotmatics is attempting to alter the future of scientific software and data management

Dotmatics is attempting to alter the future of scientific software and data management ...

The brand of Insightful Science and Dotmatics has been announced as the official name and brand for the new company. Dotmatics now includes the Dotmatics enterprise scientific platform and many of the scientists favorite applications including SnapGene, Geneious, and GraphPad Prism to offer end-to-end solutions for biology, chemistry, and formulations research and development.

Scientific knowledge and growth in pharmaceutical drug discovery and chemicals & materials innovation are evolving at a rapid pace than ever before.

COVID stated that scientific research and collaboration are needed to be accelerated for faster, more successful breakthroughs. Yet the complexity of getting and using scientific data in meaningful ways has resulted in deteriorating success and lag in findings. The business has been missing an integrated R&D platform with the ability to broaden, breadth, and connect to other applications to address the complex data challenges in labs.

To overcome workflow and data complexity, Dotmatics integrates an integrated R&D platform with applications.

Dotmatics has built a platform that connects and organizes information that is distributed across organizations or industries and combines it with market-leading science applications for quick access, collaboration, and informed decision-making.

Companies that have the finest, most well-known data to compete in their AI analytics and decision making will be the best positioned to succeed in this new paradigm, according to Thomas Swalla, the company''s CEO. We will be launching under the consolidated brand Dotmatics, which shows the company''s enormous power to provide this capability to our customers. We can transform scientific research and research with a platform that addresses the data challenges and then connects industry-favorite applications to better harmonize science and data.

Debiopharm, an established organization aiming to improve their science and data, is developing innovative therapies that help with unmet medical needs in oncology and infectious diseases. Together, they identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally.

"Dotmatics has erupted the way Debiopharm works for the better," says Rene van den Bersselaar, the CEO of Debiopharm, who has driven change in the business. They are now making better, more data-driven decisions, helping us be more competitive and making the necessary adjustments necessary to produce new therapies for patients.

Dotmatics is a global network of internationally recognised biotech, biopharma, chemicals & materials companies, and academic institutions that are collaborating to accelerate innovation and make the world a healthier, cleaner, and safer place to live.

Dotmatics'' combined team of 800+ employees is working together to overcome the challenges and workarounds facing today''s market. Today, we are assisting companies like BAS-F, Merck, and Novartis Pharma AG, as well as research universities like MIT and Oxford, by providing them with solutions that harmonise science and data.

After the merger of Insightful Science and Dotmatics in March 2021, a global team of 800+ employees has provided support to Dotmatics'' customers in over 180 countries. It has recently added senior executive positions including a CFO, a CRO, and a CMO, and will continue to build and acquire innovative scientific software solutions in this year. Dotmatics has invested $1 billion in capital to acquire five of the most powerful scientific software applications that are critical in laboratory research.

You may also like: